-
Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study -
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform -
Scipher Medicine Publishes New Data Further Supporting Clinical Utility of PrismRA Blood Test -
Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium - Scipher Medicine Closes $110 Million Financing
-
Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference -
Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA Blood Test -
Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference -
Scipher Medicine Appoints Richard Blackburn to its Advisory Board -
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago -
Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board - America’s Choice Provider Network Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
- Scipher Medicine® Appoints Sam Asgarian, M.D., MBA, Chief Medical Officer
-
GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis -
Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways